These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8029802

  • 1. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
    White BP, Sullivan AT, Lumley P.
    Thromb Haemost; 1994 Mar; 71(3):366-74. PubMed ID: 8029802
    [Abstract] [Full Text] [Related]

  • 2. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
    Takiguchi Y, Wada K, Nakashima M.
    Thromb Haemost; 1992 Oct 05; 68(4):460-3. PubMed ID: 1448780
    [Abstract] [Full Text] [Related]

  • 4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M, Mantz F, Nicolini P, Gachet C, Mulvihill J, Meyer L, Beretz A, Cazenave JP.
    Thromb Haemost; 1993 May 03; 69(5):515-21. PubMed ID: 8322274
    [Abstract] [Full Text] [Related]

  • 5. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 03; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 6. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ.
    J Pharmacol Exp Ther; 1988 Aug 03; 246(2):790-6. PubMed ID: 3136245
    [Abstract] [Full Text] [Related]

  • 7. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig.
    Hirata Y, Takiguchi Y, Wada K, Matsuno H, Umemura K, Uematsu T, Nakashima M.
    Eur J Pharmacol; 1993 Feb 16; 231(3):421-5. PubMed ID: 8449234
    [Abstract] [Full Text] [Related]

  • 8. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    Kitai T, Nishikawa M, Tanigawa T, Okinaka T, Wada H, Shiku H, Ikeda Y, Ito M, Isaka N, Nakano T.
    Am Heart J; 2001 Aug 16; 142(2):E1. PubMed ID: 11479480
    [Abstract] [Full Text] [Related]

  • 9. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
    Umemura K, Kawai H, Ishihara H, Nakashima M.
    Jpn J Pharmacol; 1995 Mar 04; 67(3):253-8. PubMed ID: 7630043
    [Abstract] [Full Text] [Related]

  • 11. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD, Müller TH.
    Basic Res Cardiol; 1997 Jun 04; 92(3):181-90. PubMed ID: 9226103
    [Abstract] [Full Text] [Related]

  • 12. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep 04; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 13. Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.
    Hasa AA, Schmaier AH, Warnock M, Normolle D, Driscoll E, Lucchesi BR, Werns SW.
    Thromb Haemost; 2001 Nov 04; 86(5):1296-304. PubMed ID: 11816721
    [Abstract] [Full Text] [Related]

  • 14. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
    Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L.
    Circulation; 1998 Feb 24; 97(7):681-5. PubMed ID: 9495304
    [Abstract] [Full Text] [Related]

  • 15. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Fiedler VB, Perzborn E, Seuter F, Rosentreter U, Böshagen H.
    Arzneimittelforschung; 1989 Dec 24; 39(12):1527-30. PubMed ID: 2624600
    [Abstract] [Full Text] [Related]

  • 16. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
    Matsuno H, Kozawa O, Nagashima S, Kanamaru M, Uematsu T.
    Br J Pharmacol; 1999 Jul 24; 127(5):1129-34. PubMed ID: 10455258
    [Abstract] [Full Text] [Related]

  • 17. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin.
    Lumley P, Keery RJ, Wharton KA, White BP, Watts IS.
    Adv Prostaglandin Thromboxane Leukot Res; 1991 Jul 24; 21B():603-6. PubMed ID: 1825385
    [No Abstract] [Full Text] [Related]

  • 18. [Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction].
    Kremneva LV, Shalaev SV.
    Ter Arkh; 2008 Jul 24; 80(12):89-95. PubMed ID: 19227916
    [No Abstract] [Full Text] [Related]

  • 19. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
    Herbert JM, Dol F, Bernat A, Falotico R, Lalé A, Savi P.
    Thromb Haemost; 1998 Sep 24; 80(3):512-8. PubMed ID: 9759636
    [Abstract] [Full Text] [Related]

  • 20. Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina.
    Bierbach B, Horstick G, Berg O, Heimann A, Münzel T, Vahl CF, Kempski O, Darius H.
    Thromb Haemost; 2006 Feb 24; 95(2):354-61. PubMed ID: 16502561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.